-
-
-
-
-
-
-
PEPFAR and Global Fund expand lenacapavir access to 1 million more people
-
-
-
-
-
-
-
Gilead Sciences (GILD) PT Raised to $160 at BMO Capital
-
-
-
-
-
-
-
UBS Assumes Gilead Sciences (GILD) at Buy
-
-
-
-
-
-
-
Gilead Sciences (GILD) Tops Q3 EPS by 32c; offers guidance
-
-
-
-
-
-
-
Buy this U.S. large-cap biopharma stock: JPMorgan
-
-
-
-
-
-
-
Gilead Presents New Data on Twice-Yearly Lenacapavir (Yeztugo®) for HIV Prevention at IAS 2025
-
-
-
-
-
-
-
Gilead Sciences (GILD) Tops Q1 EPS by 4c; maintains guidance
-
1,197,267 total articles have been posted to this entity.
Click Here to Sign-Up for StreetInsider.com Premium to View All

